Novartis Oncology China Appoints New Heads for Hematology and Rare Diseases Business Units

The Heads of the Hematology and Rare Diseases Division at Novartis Oncology (China) Have Been Confirmed!

On December 5, Ji Bicheng, General Manager of Novartis Oncology (China), announced to employees the appointment of Zhou You, current Head of Business Optimization, as Head of the Rare Disease Division of Novartis Oncology (China), effective January 2, 2020; and the appointment of Cai Hua as Head of the Hematology Division of Novartis Oncology (China), effective January 6, 2020.

Below is a brief introduction to these two new leaders, as per usual.

After graduating from Peking Union Medical College in Beijing in 2005, Zhou You worked as a physician at Peking Union Medical College Hospital for two years, then joined McKinsey & Company as a business manager, and in 2011 joined China Resources Group as a senior researcher.

In April 2013, Zhou You joined Novartis Oncology as Head of Strategy. In July 2014, he assumed the role of Head of Business Optimization, a position he continues to hold, with responsibilities encompassing Sales Force Effectiveness (SFE), business analytics, digital innovation, and market research. From 2014 to 2017, he also served as Head of Rare Disease Marketing.

Cai Hua, who is about to assume the role of Head of the Hematology Business Unit, currently serves as Senior Marketing Director for Pfizer’s Oncology Products. From 2003 to 2005, he worked at Eli Lilly as Product Manager for olanzapine. He subsequently joined Pfizer China, where he held various positions including Product Manager, Regional Manager, Deputy Sales Director for the Northern Region, and Head of the Internal Medicine Marketing Team. In May 2018, he was appointed Senior Marketing Director for Oncology Products at Pfizer China.

▋Former person in charge Wang Mingxin left his post in October

As previously reported by Dami, Novartis Oncology originally had two business units in China: the Hematology & Rare Diseases Division and the Solid Tumors Division. Since 2016, Wang Mingxin has been leading the Hematology & Rare Diseases Division of Novartis Oncology (China). In early July this year, Novartis Oncology (China) announced that Wang Mingxin would be reassigned as the Head of Business Development and Licensing (BD&L), with no successor announced at the time.

Subsequently, Novartis Oncology announced a new organizational structure, with HEMA and RARE operating as fully separate lines. Novartis Oncology’s business in China is now divided into three teams: Hematologic Malignancies, Rare Diseases, and Solid Tumors.

On October 18 this year, Novartis Oncology (China) announced that Wang Mingxin had decided to leave Novartis to pursue external opportunities.